Pfizer and Astellas Pharma have shared positive top-line results from a late-stage study of their androgen receptor signalling inhibitor Xtandi (enzalutamide) in a subset of prostate cancer patients.

Plants express a family of immune receptors called NLRs, which are classified into three subtypes known as TNLs, CNLs and ...